Reuters -- Britain’s SkyePharma said on Thursday the U.S regulator has set tougher than expected demands for approval of its asthma drug Flutiform, which may prove insurmountable.
Reuters -- Britain’s SkyePharma said on Thursday the U.S regulator has set tougher than expected demands for approval of its asthma drug Flutiform, which may prove insurmountable.
